LETTER TO THE EDITOR

Atenolol, bendrofluazide and their use in combination
In a recent issue of the Journal, Johnson et al 1 reported on a low dose atenolol/bendrofluazide combination in patients with mild to moderate hypertension, and came to the conclusion that the combination therapy was better than either of the individual drugs using lower doses. However I have a problem with the design of the study, which prevents this conclusion being reached.
The study design was a parallel design study comparing atenolol 50 mg, bendrofluazide 2.5 mg, atenolol 25 mg + bendrofluazide 1.25 mg and placebo. I have no objection to the conclusion that the low dose combination is more effective than either of the two other drugs. However what cannot be determined is whether this is because the combination therapy is more effective in all patients, or whether it recruits additional patients. Thus the results could be due to the following scenario.
Fifty per cent of the atenolol patients may have responded to either 25 or 50 mg and the others not responded at all. Likewise 50% of the bendrofluazide 2.5 mg patients may have responded and the others not at all. If there is no crossover between the responders in the atenolol and the bendrofluazide group the combination therapy will clearly appear to be more effective as now 100% rather than 50% will respond. However, it may not be more effective than the better of the responses to either atenolol or bendrofluazide as monotherapy.
The only way to come to the conclusion that a combination therapy is better than monotherapy is to do a crossover factorial study of the agents, the combination and placebo. In this way results can be achieved and when the comparison is made the fall with the combination is compared with the better of the fall with either of the two individual components. We have followed this design in a previous study 2 and came to the conclusion that the combination of an ACE inhibitor and felodipine was in fact at least additive and was better in low doses than increasing the dose of either drugs.
I expect their conclusions are correct. It may prove to be better not only to use low dose drug combination when single dose therapy is less than optimal, but possibly to use low dose therapy as initial medication.
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